A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 387, Issue 6, 2014, Pages 505-521

  Modjtahedi, Helmout ^a   Cho, Byoung Chul ^b   Michel, Martin C ^c,d   Solca, Flavio ^e  

^a KINGSTON UNIVERSITY   (United Kingdom)

^b Yonsei University College of Medicine   (South Korea)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

Author keywords

Afatinib; Combination treatment; Epidermal growth factor receptor; Non small cell lung cancer; Resistance

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AFATINIB; AZ 9192; CANERTINIB; CETUXIMAB; CO 1686; CYSTEINE; DACOMITINIB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; JANUS KINASE INHIBITOR; LAPATINIB; NERATINIB; NINTEDANIB; PANITUMUMAB; PEMETREXED; PERTUZUMAB; POZIOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHOSPHORYLATION; BREAST CANCER; CANCER CELL LINE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CELL GROWTH; COLORECTAL CANCER; CONCENTRATION RESPONSE; COVALENT BOND; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PANCREAS CANCER; PROTEIN PHOSPHORYLATION; REVIEW; RODENT; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DOSE RESPONSE; METABOLISM; NEOPLASMS; PHYSIOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERBB RECEPTORS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84901355015     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-014-0967-3     Document Type: Review

References (104)

1. Aravindan N, Thomas CR, Aravindan S, Mohan AS, Veeraraghavan J, Natarajan M (2011) Irreversible EGFR inhibitor EKB-569 targets low-LET γ-radiation-triggered Rel orchestration and potentiates cell death in squamous cell carcinoma. PLoS ONE 6:e29705
2. Barf T, Kaptein A (2012) Irreversible protein kinase inhibitors: balancing the benefits and risks. J Med Chem 55:6243-6262
3. Bean J, Riely GJ, Balak M, Marks JL, Ladanyi M, Miller VA, Pao W (2008) Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung carcinoma. Clin Cancer Res 14:7519-7525
4. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O'Shaugnessy J (2010) Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive trastuzumab-refractory metastatic breast cancer. J Clin Oncol 27:1124-1130
5. Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, Monsey J, Goel N, Aronson AB, Li S, Ma CX, Ding L, Mardis ER, Ellis MJ (2013) Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 3:224-237
6. Boyraz B, Sendur MAN, Aksoy S, Babacan T, Roach EC, Kizilarslanoglu MC, Petekkaya I, Altundag K (2013) Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Curr Med Res Opin 29:405-414
7. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S (2003) An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 12:541-552 (Pubitemid 37222478)
8. Canonici A, Pedersen K, Browne B, McDermott M, Walsh N, Crown J, O'Donovan N (2013) Effect of afatinib alone and in combination with trastuzumab in HER2-positive breast cancer cell lines. J Clin Oncol 31(Suppl):632
9. Cha MY, Lee K-O, Kim M, Song JY, Lee KH, Park J, Chae YJ, Kim YH, Suh KH, Lee GS, Park SB, Kim MS (2012) Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Int J Cancer 130:2445-2454
10. Chang AY, Wang M (2012) Synergistic interactions of gefitinib, afatinib, cetuximab and dasatinib against gefitinib resistant non-small cell lung cancer (NSCLC). J Thoracic Oncol 7(Suppl 5):S453
11. Chen Y-J (2012) Mechanisms underlying resistance to epidermal growth factor receptor inhibitors in non-small cell lung cancer. Biol Biomed Rep 2:141-148
12. Chen G, Kronenberger P, Teugels E, Umerlo IA, De Greve J (2012) Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Med 10:28
13. Chmielecki J, Pietanza C, Aftab D, Shen R, Zhao Z, Chen X, Hutchinson K, Viale A, Kris MG, Stout T, Miller V, Rizvi N, Pao W (2012) EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib. J Thoracic Oncol 7:434-442
14. Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. New Engl J Med 358:1160-1174
15. Cohen S (1962) Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem 237:1555-1562
16. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 29:1046-1051
17. De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D, Pinto A, Normanno N (2008) The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 214:559-567 (Pubitemid 351224199)
18. Eberl M, Klingler S, Mangelberger D, Loipetzberger A, Damhofer H, Zoidl K, Schnidar H, Hache H, Bauer H-C, Solca F, Hauser-Kronberger C, Ermilov AN, Verhaegen ME, Bichakjian CK, Dlugosz AA, Nietfeld W, Sibilia M, Lehrach H, Wierling C, Aberger F (2012) Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour-initiating pancreatic cancer cells. EMBO Mol Med 4:218-213
19. Engelman JA, Settleman J (2008) Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev 18:73-79 (Pubitemid 351694445)
20. Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, Lifshits E, Brown A, Lee C, Christensen JG, Kwiatkowski DJ, Engelman JA, Jänne PA (2010) Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 29:2346-2356
21. Ercan D, Xie T, Capelletti M, Gray NS, Janne PA (2012) Novel EGFR mutations that cause drug resistance to irreversible pyrimidine but not quinazoline based EGFR inhibitors. Cancer Res 72:4832
22. Gazdar AF (2009) Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28:S24-S31
23. Graus-Porta D, Beerli RR, Daly JM, Hynes NE (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16:1647-1655 (Pubitemid 27151960)
24. Greulich H, Kaplan B, Mertins P, Chen T-H, Tanaka KE, Yun C-H, Zhang X, Lee S-H, Cho J, Ambrogio L, Liao R, Imielinski M, Banerji S, Berger AH, Lawrence MS, Zhang J, Pho NH, Walker SR, Winckler W, Getz G, Frank D, Hahn WC, Eck MJ, Mani DR, Jaffe JD, Carr SA, Wong K-K, Meyerson M (2012) Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A 109:14476-14481
25. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, Engelman JA (2008) Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 118:2609-2619 (Pubitemid 351949788)
26. Hammerman PS, Jänne PA, Johnson BE (2009) Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 15:7502-7509
27. Harbeck N, Solca F, Gauler TC (2014) Afatinib in breast cancer and squamous cell carcinoma of the head and neck. Future Oncol 10:21-40
28. Heiser LM, Sadanandam A, Kuo W-L, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, Dueregger A, Lewis S, Jakkula L, Korkola JE, Durinck S, Pepin F, Guan Y, Purdom E, Neuvial P, Bengtsson H, Wood KW, Smith PG, Vassilev L, Hennessy BT, Greshock J, Bachman KE, Hardwicke MA, Park JW, Marton LJ, Wolf DM, Collisson EA, Neve RM, Mills GB, Speed TP, Feiler HS, Wooster RF, Haussler D, Stuat JM, Gray JW, Spellman PT (2012) Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A 109:2724-2729
29. Held MA, Langdon CG, Platt JT, Graham-Steed T, Liu Z, Chakraborty A, Bacchiocchi A, Koo A, Haskins JW, Bosenberg MW, Stern DF (2013) Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov 3:52-67
30. Holbro T, Hynes NE (2004) ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 44:195-217 (Pubitemid 38263839)
31. Hollmen M, Elenius K (2010) Potential of ErbB4 antibodies for cancer therapy. Future Oncol 6:37-53
32. Horn L, Sandler A (2009) Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer. Clin Cancer Res 15:5040-5048
33. Hsu J, Lin W, Lien T, Chang W, Sun M, Jiang S, Yen K, Chao Y (2012) Overcoming acquired resistance to afatinib in HCC827, a non-small cell lung cancer cell line. Eur J Cancer 48:47
34. Hurvitz SA, Kakkar R (2012) Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer. Breast Cancer Targ Ther 4:35-51
35. Ioannou N, Dalgleish A, Seddon AM, Mackintosh D, Guertler U, Solca F, Modjtahedi H (2011) Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. Br J Cancer 105:1554-1562
36. Ioannou N, Seddon AM, Dalgleish A, Mackintosh D, Modjtahedi H (2012) Expression pattern and targeting of HER family members and IGF-IR in pancreatic cancer. Front Biosci 17:2698-2724
37. Ioannou N, Seddon AM, Dalgleish A, Mackintosh D, Modjtahedi H (2013) Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells. BMC Cancer 13:41
38. Jaiswal BS, Kijavin NM, Stawiski EW, Chan E, Parikh C, Durinck S, Chaudhuri S, Pujara K, Guillory J, Edgar KA, Janakiraman V, Scholz RP, Bowman KK, Lorenzo M, Li H, Wu J, Yuan W, Peters BA, Kan Z, Stinson J, Mak M, Modrusan Z, Eigenbrot C, Firestein R, Stern HM, Rajalingam K, Schaefer G, Merchant MA, Sliwkowski MX, de Sauvage FJ, Seshagiri S (2013) Oncogenic ErbB3 mutations in human cancers. Cancer Cell 23:603-617
39. Janjigian YY, Smit EF, Horn L, Groen HJM, Camidge DR, Gettinger S, Fu Y, Denis LJ, Miller V, Pao W (2012) Activity of afatinib/cetuximab in patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) and acquired resistance (AR) to EGFR inhibitors. European Society for Medical Oncology 37th Congress, Vienna, Austria, 28-Sep to 2-Oct, 2012. Ann Oncol 23(Suppl 9). Abstract #1227O
40. 89Zr-trastuzumab PET. J Nucl Med 54:936-943
41. Kanda R, Kawahara A, Watari K, Murakami Y, Sonoda K, Maeda M, Fujita H, Kage M, Uramoto H, Costa C, Kuwano M, Ono M (2013) Erlotinib resistance in lung cancer cells mediated by integrinaß1/Src/Akt-driven bypass signaling. Cancer Res 73:6243-6253
42. Khelwatty SA, Essapen S, Seddon AM, Modjtahedi H (2011) Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members. Int J Oncol 39:483-491
43. Khelwatty SA, Essapen S, Seddon AM, Modjtahedi H (2013) Prognostic significance and targeting of HER family in colorectal cancer. Front Biosci 18:394-421
44. Kim SM, Kwon O-J, Hong YK, Kim JH, Solca F, Ha S-J, Soo RA, Christensen JG, Lee JH, Cho BC (2012a) Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol Cancer Ther 11:2254-2264
45. Kim Y, Ko J, Cui ZY, Abolhoda A, Ahn JS, Ou S-H, Ahn M-J, Park K (2012b) The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol Cancer Ther 11:784-791
46. Kim SM, Yun MR, Hong YK, Solca F, Kim JH, Kim HJ, Cho BC (2013) Glycolysis inhibition sensitizes non-small cell lung cancer with T790M mutation to irreversible EGFR inhibitors via translational suppression of Mcl-1 by AMPK activation. Mol Cancer Ther 12:2145-2156
47. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. New Engl J Med 352:786-792 (Pubitemid 40271173)
48. Köhler J, Breitenbuecher F, Hoffarth S, Schuler M (2012) Mechanisms of resistance of non-small cell lung cancer (NSCLC) against tyrosine kinase inhibitors of the epidermal growth receptor (EGFR TKI). Abstract Book CESAR meeting 49
49. Kumar A, Petri ET, Halmos B, Boggon TJ (2008) Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 26:1742-1751
50. La Motta C, Sartini S, Tuccinardi T, Nerini E, Da Settimo F, Martinelli A (2009) Computational studies of epidermal growth factor receptor: docking reliability, three dimensional quantitative structure-activity relationship analysis, and virtual screening results. J Med Chem 52:964-975
51. Langer CJ (2013) Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer? J Clin Oncol 31:3303-3306
52. Lee H-J, Schaefer G, Heffron TP, Shao L, Ye X, Sideris S, Malek S, Chan E, Merchant M, La H, Ubhayakar S, Yauch RL, Pirazzoli V, Politi K, Settleman J (2013) Noncovalent wild-type sparing inhibitors of EGFR T790M. Cancer Discov 3:168-181
53. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H, Wong K-K (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27:4702-4711
54. Lin L, Bivona TG (2012) Mechanisms of resistance to epidermal growth factor receptor inhibitors and novel therapeutic strategies to overcome resistance in NSCLC patients. Chemother Res Pract 2012:817297
55. Mack PC, Goodwin N, Holland WS, Kelly K, Lara P, Gandara DR (2013) Differential activity of afatinib (AFAT), cetuximab (CET), and erlotinib (E) in a patient-derived xenograft (PDX) model of acquired E resistance. J Clin Oncol 31(Suppl):8110
56. Modjtahedi H, Dean C (1994) The receptor for EGF and its ligands - expression, prognostic value and target for therapy in cancer. Int J Oncol 4:277-296 (Pubitemid 24039840)
57. Nam H-J, Kim H-P, Yoon Y-K, Hur H-S, Song S-H, Kim M-S, Lee G-S, Han S-W, Im S-A, Kim T-Y, Oh D-Y, Bang Y-J (2011) Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer. Cancer Lett 302:155-165
58. Nam H-J, Ching KA, Kan J, Kim H-P, Han S-W, Im S-A, Kim T-Y, Christensen JG, Oh D-Y, Bang Y-J (2012a) Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer. Mol Cancer Ther 11:439-451
59. Nam H-J, Kim H-P, Yoon Y-K, Song S-H, Min A-R, Han S-W, Im S-A, Kim T-Y, Oh D-Y, Bang Y-J (2012b) The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines. Invest New Drugs 30:2148-2160
60. Nanjo S, Yamada T, Nakagawa T, Takeuchi S, Mtsudomi T, Yano S (2012) Combined therapy with next generation EGFR inhibitor and met kinase inhibitor for overcoming the resistance in EGFR mutant lung cancer. J Thoracic Oncol 7(Suppl 5):S453
61. Nelson V, Ziehr J, Agulnik M, Johnson M (2013) Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. OncoTargets Ther 6:135-143
62. Nguyen K-SH, Kobayashi S, Costa DB (2009) Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 10:281-289
63. Nie W, Tang L, Zhang H, Shao J, Wang Y, Chen L, Li D, Guan X (2012) Structural analysis of the EGFR TK domain and potential implications for EGFR targeted therapy. Int J Oncol 40:1763-1769
64. Ninomiya T, Takigawa N, Ichihara E, Ochi N, Murakami T, Honda Y, Kubo T, Minami D, Kudo K, Tanimoto M, Kiura K (2013) Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model. Mol Cancer Ther 12:589-597
65. O'Neill F, Madden SF, Clynes M, Doolan P, Crown J, Aherne S, O'Connor R (2013) A gene expression profile indicative of early stage HER2 tyrosine kinase inhibitor response. J Clin Oncol 31(Suppl):e11536
66. Pan Y, Xu Y, Feng S, Luo S, Zheng R, Yang J, Wang L, Zhong L, Yang HY, Wang B-L, Yu Y, Liu J, Cao Z, Wang X, Ji P, Wang Z, Chen X, Zhang S, Wei Y-Q, Yang S-Y (2012) SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo. Mol Cancer Ther 11:952-962
67. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73
68. Pareja F, Ferraro DA, Rubin C, Cohen-Dyashi H, Zhang F, Aulmann S, Ben-Chetrit N, Pines G, Navon R, Crosetto N, Köstler W, Carvalho S, Lavi S, Schmitt F, Dikic I, Yakhini Z, Sinn P, Mills GB, Yarden Y (2012) Deubiquitination of EGFR by Cezanne-1 contributes to cancer progression. Oncogene 31:4599-4608
69. Park JW, Stagg R, Lewis GD, Carter P, Maneval D, Slamon DJ, Jaffe H, Shepard HM (1992) Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy. Cancer Treat Res 61:193-211
70. YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci U S A 106:474-479
71. Perez EA, Romond EH, Suman VJ, Jeong J-H, Davidson NE, Geyer CE, Martino S, Mamounas EP, Kaufman PA, Wolmark N (2011) Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366-3373
72. Pfeifer M, Weiss J, Sos ML, Koker M, Heynck S, Netzer C, Fischer S, Rode H, Rauh D, Rahnenführer J, Thomas RK (2010) Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling. PLoS ONE 5:e8919
73. Poindessous V, Ouaret D, El Ouadrani K, Battistella A, Megalophonos VF, Kamsu-Kom N, Petitprez A, Escargueil AE, Boudou P, Dumont S, Cervera P, Flejou J-F, Andre T, Tournigand C, Chibaudel B, de Gramont A, Larsen AK (2011) EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies. Clin Cancer Res 17:6522-6530
74. Press MF, Jones LA, Godolphin W, Edwards CL, Slamon DJ (1990) HER-2/neu oncogene amplification and expression in breast and ovarian cancers. Prog Clin Biol Res 354A:209-221
75. Prickett TD, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich JR, Cronin JC, Cruz P, Rosenberg SA, Samuels Y (2009) Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ErbB4. Nat Genet 41:1127-1132
76. Quesnelle KM, Grandis JR (2011) Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clin Cancer Res 17:5935-5944
77. Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A, Koutcher JA, Spassova M, Querfelli Q, Mellinghoff IK, Zakowski MF, Politi KA, Pao W (2009) Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 119:3000-3010
78. Rho JK, Choi YJ, Choi YR, Kim SY, Choi SJ, Na II, Lee JC (2011) The effects of acquired cisplatin resistance on sensitivity to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer cells. Oncol Res 19:471-478
79. Rjr R (2014) The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 79:34-74
80. Savage CR, Inagami T, Cohen S (1972) The primary structure of epidermal growth factor. J Biol Chem 247:7612-7621
81. Schütze C, Dörfler A, Eicheler W, Zips D, Hering S, Solca F, Baumann M, Krause M (2007) Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW2992 and BIBW2669 with irradiation in FaDu human squamous cell carcinoma. Strahlentherapie Onkologie 183:256-264 (Pubitemid 46725991)
82. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Mino-Kenudson M, Engelman JA (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3:75ra26
83. Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA (2010) ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci U S A 107:7692-7697
84. Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H, Wistuba II, Fong KM, Toyooka S, Shimizu N, Fujisawa T, Minna JD, Gazdar AF (2005) Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 65:1642-1646 (Pubitemid 40478587)
85. Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E, Adolf GR (2012) Target binding properties and cellular activity of afatinib (BBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 343:342-350
86. Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, Seeger JM, Weiss J, Fischer F, Frommolt P, Michel K, Pfeifer M, Mermel C, Girard L, Peyton M, Gazdar AF, Minna JD, Garraway LA, Kashkar H, Pao W, Meyerson M, Thomas RK (2009) PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 69:3256-3261
87. Sos ML, Rode HB, Heynck S, Pfeifer M, Fischer F, Klüter S, Pawar VG, Reuter C, Heuckmann JM, Weiss J, Ruddigkeit L, Rabiller M, Koker M, Simard JR, Getlik M, Yuza Y, Chen T-H, Greulich H, Thomas RK, Rauh D (2010) Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res 70:868-874
88. Sun JM, Ahn MJ, Choi YL, Ahn JS, Park K (2013) Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors. Lung Cancer 82(2):294-298
89. Tabara K, Kanda R, Sonoda K, Kubo T, Murakami Y, Kawahara A, Azuma K, Abe H, Kage M, Yoshinaga A, Tahira T, Hayashi K, Arao T, Nishio K, Rosell R, Kuwano M, Ono M (2012) Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells. PLoS ONE 7:e41017
90. Takezawa K, Okamoto I, Tanizaki J, Kuwata K, Yamguchi H, Fukuoka M, Nishio K, Nakagawa K (2010) Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. Mol Cancer Ther 9:1647-1656
91. T790M mutation. Cancer Discov 2:922-933
92. Tanaka H, Ichikawa Y, Nishida K, Kondo E, Nakanishi H (2012) Antitumor and anti-metastatic effect of an irreversible TKI (afatinib) against HER2- positive gastric cancer cell lines. 71th Ann Meeting of the Japanese Cancer Association (JCA), Sapporo, 19-21 Sep 2012 (Oral Presentation)
93. Tasi Y-C, Chen JCH, Tuan T-F, Yeh C-H, Ho P-Y, Pu Y-S, Cheng A-L (2012) Afatinib, an EGFR(Her-2 dual inhibitor, effectively radiosensitizes bladder cancer cells. Cancer Res 72(Suppl):1464
94. Vadakara J, Borghaei H (2012) Personalized medicine and treatment approaches in non-small-cell lung carcinoma. Pharmacogen Pers Med 5:113-123
95. Wang W, Li Q, Takeuchi S, Yamada T, Koizumi H, Nakamura T, Matsumoto K, Mukaida N, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S (2012) Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Clin Cancer Res 18:1663-1671
96. Wong ALA, Lee S-C (2012) Mechanisms of resistance to trastuzumab and novel therapeutic strategies in HER2-positive breast cancer. Int J Breast Cancer 1:415170
97. 8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations. J Med Chem 55:10685-10699
98. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137 (Pubitemid 33674041)
99. Yasuda H, Kobayashi S, Costa DB (2012) EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol 13:e23-e31
100. Yoo GH, Hung M-C, Lopez-Berestein G, LaFollette S, Ensley JF, Carey M, Batson E, Reynolds TC, Murray JL (2001) Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res 7:1237-1245 (Pubitemid 32708675)
101. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, Meyerson M, Eck MJ (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 105:2070-2075 (Pubitemid 351439466)
102. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125:1137-1149 (Pubitemid 43866200)
103. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, Greene MI (2007) ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 117:2051-2058 (Pubitemid 47224766)
104. Zhang M, Taylor CE, Piao L, Datta J, Bruno PA, Bhave S, Su T, Lang JC, Xie X, Teeknos TN, Mapp AK, Pan Q (2013) Genetic and chemical targeting of epithelial-restricted with serine box reduces epidermal growth factor receptor and potentiates the efficacy of afatinib. Mol Cancer Ther 12:1515-1525